Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (261-270 of 336) with videos related to

Pageof 34
Sort By:
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Frontiers in Immunology|May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
Frontiers in Immunology|March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Nature Medicine|January 28, 2026
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trialSerena Porcari, Chiara Ciccarese, Vitor Heidrich, et al.
Scientific Reports|March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumabLorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
Pageof 34

Showing results (261-270 of 336) with videos related to

Sort By:
Pageof 34
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Frontiers in Immunology|May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
Frontiers in Immunology|March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Nature Medicine|January 28, 2026
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trialSerena Porcari, Chiara Ciccarese, Vitor Heidrich, et al.
Scientific Reports|March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumabLorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
Pageof 34